Michael Powell, Director at Trius Therapeutics Inc (TSRX), sold 24,622 shares at $5.43 ($134K) on 2012-01-17, disclosed to the SEC on 2012-01-17.
Scheduled sale ($134k) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $5.46 | 8,522 | $47K | 34.7% |
| 2 | $5.43 | 16,100 | $87K | 65.3% |
| Total | $5.44 avg | 24,622 | $134K | 100% |
| Filing → |
| OCRX | SELL | 2016-12-30 | $15K | — | Filing → |
| MIRN | BUY | 2015-10-06 | $6.0M | — | Filing → |
| AERI | SELL | 2014-07-11 | $24.2M | — | Filing → |